Summary of Death of Cancer

Looking for the article?
We have the summary! Get the key insights in just 5 minutes.

Death of Cancer summary
Start getting smarter:
or see our plans


9 Overall

10 Importance

9 Innovation

9 Style


For decades, battles have been fought in the war on cancer. Soon, the war could and should be over. Vincent DeVita is a pioneer oncologist and former director of the National Cancer Institute. Writing with his journalist daughter Elizabeth DeVita-Raeburn, he explains in plain language the “hallmarks” of cancer cells and outlines what kind of cancer research would be necessary – if only government laws allowed it. getAbstract recommends this expert yet accessible article to cancer patients and would like to put this plea for a new cancer act into the hands of those in charge.

In this summary, you will learn

  • How far cancer research has come in the past 50 years,
  • How cancer cells develop and how treatment targets them, and
  • Why outdated regulations prevent cancer’s eradication.

About the Authors

Vincent DeVita is a professor at Yale and the former director of the National Cancer Institute. His daughter Elizabeth DeVita-Raeburn is a science journalist.



In the past, cancer was a taboo subject, a dead-end medical research field and lethal enemy. Since 1971, when former US president Richard Nixon signed the National Cancer Act, cancer awareness has increased. Research has generated more sophisticated methods and technologies for curing cancer and enhancing the comfort of cancer patients. Three major breakthroughs have led to significant declines in cancer mortality: First, realizing that a mix of drugs could heal advanced cancer produced effective chemotherapy. Second, researchers developed targeted therapy – that is, drugs...

More on this topic

Customers who read this summary also read

A Radically Simple Idea Will Let Us Catch Cancer Before It’s Cancer
Technology Quarterly: Targeting Tumours
Immune System, Unleashed by Cancer Therapies, Can Attack Organs
In a Major Shift, Cancer Drugs Go ‘Tissue-Agnostic’
Cancer Pill Costs Soar as Drug Companies Retain Pricing Power
Killer Clones

Related Channels

Comment on this summary